Filing Flows › Cytokinetics (CYTK) › Q3 2026
Cytokinetics (CYTK) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Cytokinetics (CYTK) reported revenue of $47.6M for the third quarter 2026 (Q3 2026), up 25-fold from a year earlier and +66% from the quarter before. Operating margin was -351.3%, net loss $190M (399.7% of revenue).
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $47.6M | +66% | 25× |
| Operating profit | −$167M | — | — |
| Net earnings | −$190M | — | — |
| Operating cash flow | −$124M | — | — |
What changed
Revenue was $47.6M in Q3 2026, up 2356% year over year and up 66% from the previous quarter. Net Product Revenue was the largest line at 94% of revenue. Collaboration Revenues added $1.1M year over year (up 58%), 2% of the total change.
Operating costs exceeded revenue by $167.1M, an operating margin of -351.3%. Total costs grew 27% against revenue growth of 2356%. The fastest-growing cost line was SG&A (+63%). The quarter ended with a net loss of $190.1M, narrower than the previous quarter's $198.8M loss.
Operating cash flow was −$124.0M. Non-cash charges added back $3.6M of depreciation and amortization and $34.7M of share-based compensation. Working capital and other items added $27.7M. Capital expenditures of $700K exceeded it, leaving free cash flow of −$124.7M.
Questions
What was Cytokinetics' revenue in the third quarter 2026?
Cytokinetics (CYTK) reported revenue of $47.6M for the third quarter 2026 (Q3 2026), up 25-fold from a year earlier and +66% from the quarter before.
Was Cytokinetics profitable in the third quarter 2026?
Operating loss was $167M (-351.3% of revenue) and net loss $190M.
Source: Cytokinetics 10-Q on SEC EDGAR.